Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.49 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22877075 | 0.81 | HCRTR1 (0.51) | GABBR2GABBR1ULK1HCRTR1KMT2A | |
| SCHEMBL22877176 | 0.81 | HCRTR1 (0.48) | GABBR2GABBR1ULK1HCRTR1KMT2A | |
| SCHEMBL17166533 | 0.80 | HCRTR1 (0.54) | HCRTR1 | |
| SCHEMBL22877019 | 0.80 | HCRTR1 (0.54) | HCRTR1 | |
| SCHEMBL17017337 | 0.79 | HCRTR1 (0.53) | HCRTR1 | |
| SCHEMBL17028066 | 0.77 | HCRTR1 (0.65) | HCRTR1 | |
| SCHEMBL17007140 | 0.77 | HCRTR1 (0.65) | HCRTR1 | |
| SCHEMBL22877217 | 0.74 | GABBR2 (0.53) | GABBR2GABBR1ULK1HCRTR1KMT2A | |
| SCHEMBL17007313 | 0.72 | HCRTR1 (0.59) | HCRTR1 | |
| SCHEMBL17031679 | 0.71 | HCRTR1 (0.49) | ULK1HCRTR1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |